Copyright
©2010 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Oct 14, 2010; 16(38): 4823-4831
Published online Oct 14, 2010. doi: 10.3748/wjg.v16.i38.4823
Published online Oct 14, 2010. doi: 10.3748/wjg.v16.i38.4823
Tumor budding predicts response to anti-EGFR therapies in metastatic colorectal cancer patients
Inti Zlobec, Tatjana Vlajnic, Alessandro Lugli, Institute for Pathology, University Hospital Basel, Basel 4031, Switzerland
Francesca Molinari, Vittoria Martin, Luca Mazzucchelli, Rosangela Trezzi, Milo Frattini, Institute of Pathology, Locarno 6600, Switzerland
Piercarlo Saletti, Sara De Dosso, Division of Medical Oncology, Institute of Southern Switzerland, Bellinzona 6500, Switzerland
Author contributions: Zlobec I was responsible for study design, statistical analysis and data interpretation; Lugli A was responsible for study design and data interpretation; Vlajnic T was responsible for histological evaluation; Molinari F, Martin V, Mazzucchelli L and Frattini M were responsible for molecular analysis and interpretation; all authors contributed to manuscript editing and final approval.
Correspondence to: Dr. Inti Zlobec, PhD, Institute for Pathology, University Hospital Basel, Schoenbeinstrasse 40, Basel, 4031, Switzerland. izlobec@uhbs.ch
Telephone: +41-61-2652895 Fax: +41-61-2652966
Received: May 20, 2010
Revised: July 9, 2010
Accepted: July 16, 2010
Published online: October 14, 2010
Revised: July 9, 2010
Accepted: July 16, 2010
Published online: October 14, 2010
Core Tip